This paper makes two contributions to the literature. We document the first evidence of causal spillover effects of health behavior choices between spouses by leveraging experimental data within RCT settings. Second, we discuss the implications of social spillovers for program evaluation in health settings; current methods of cost effectiveness and cost benefit analysis implicitly assume zero spillovers among social ties. This assumption can both underestimate the benefits of health interventions and misallocate resources toward interventions with lower comprehensive (direct + indirect) benefits due to the lack of incorporating indirect benefits. Specifically, we use data from the Lung Health Study (LHS) and COMBINE Study to estimate spillovers on smoking and drinking, respectively.
Introduction
Large literatures in public health and health economics have provided evidence that health behaviors, such as tobacco use (Franks, Pienta, and Wray, 2002; Clarke and Etilé, 2006; Falba and Sindelar, 2007; Christakis and Fowler, 2008; Cobb et al, 2014) and alcohol use (Falba and Sindelar, 2007) , are highly correlated among spouses (Meyler, Stimpson, and Peek, 2007) . Additionally, several models of household decision making suggest the importance of a co-determination of consumption and related decisions, including labor market outcomes (Goux, Maurin, and Petrongolo, 2014; Hospido and Zamarro, 2014) as well as health related behaviors (McGeary, 2013) 2 . However, some
analyses that attempt to separate causal and selection pathways suggest that selection is the main explanation for the correlation between spouses (Clarke and Etilé, 2006) . On the other hand, experimental evidence using other social ties find causal spillovers, such as in roommate smoking and drinking (Eisenberg, Golberstein, and Whitlock, 2014) . No current research has been able to leverage experimental designs to estimate causal effects of health behaviors between spouses. We use data from two health randomized controlled trials (RCTs) to fill in this gap in the literature. In addition to providing novel causal effects of spillovers of health behaviors, our analysis also has implications for program evaluation of RCTs in health settings. Although RCTs are widely considered to be the gold standard for detecting causal effects of treatments, the clean estimates they afford are often limited by the focus of data collection and analysis on subjects alone. Such estimates inform cost-effectiveness comparisons between interventions, which have increased impact due to the passage of the ACA and introduction of PCORI. While experiments provide clean estimates of treatment effects for trial subjects, evaluations generally do not account for the full social impact of an intervention through indirect effects, which may not follow the same pattern as the subject-only analysis. Social effects may occur through the utility or the behavior and outcomes of a subject's family and peers, as we show in our analysis. We examine the latter case by evaluating spousal spillover effects on substance use and calculate implications for cost-effectiveness in two addiction interventions. Not surprisingly, our causal spousal spillover estimates imply that traditional cost effectiveness analysis on the RCTs we analyze undercount the social effectiveness of the treatments. Our comprehensive cost-effectiveness analysis finds that including spillovers decreases the incremental cost effectiveness ratios of Lung Health Study treatments by 13.8 to 15.5 percent and the COMBINE therapy treatment by 9.6 percent. Importantly if these treatments also have spillover effects on non-spousal social ties (friends), our estimates still undercount these potential benefits. We also present a case where naïve estimates of the total benefits of a treatment (for alcohol) suggest a comparative benefit level greater than for a our second treatment (for tobacco use), however our more comprehensive estimates flip this comparison, suggesting the importance of estimating social spillovers both for detecting levels of treatment benefit and for relative rankings across treatments that may have different levels of indirect benefits.
Related Literature
Although there is a large literature providing evidence of spousal correlations in health (and other) behaviors and there is a small but growing literature that considers measuring social spillover effects in program evaluation, there is currently no causal evidence in the former and therefore also no specific discussion of implications for program evaluation. The former literature has had limited success producing causal estimates because of the use of non-experimental datasets; the latter literature is typified by collecting data only on treated and control individuals for purposes of evaluating programs and clinical treatment regimes. The implication of a causal relationship among socially connected individuals in health (and other) behavioral outcomes is that a treatment or program that reduces, for example, tobacco use for one adult may also reduce use for other adults within her social or family network. While there is no direct causal evidence of the existence and magnitude of these spillover effects within clinical treatment settings-and a current implicit spillover estimate of zero in evaluations-there are several related literatures that suggest the importance of spillover effects between spouses.
Quasi-experimental evidence in other contexts suggests that the correlation in health behaviors is in fact causal. For example, Eisenberg, Golberstein, and Whitlock (2014) utilize random college roommate assignment to estimate causal effects on risky behaviors, including substance use, and find strong spillovers in binge drinking, divergent spillovers by gender for smoking, and little evidence for effects on gambling, risky sexual behavior, or self-injury. A roommate's (pre-college) binge drinking increases the probability of the other roommate binge drinking by 8.6 percentage points or a 19% increase relative to baseline. The same relationship holds by gender in drinking, but a female smoking decreases her roommate's probability of smoking by a marginally significant 7.8 percentage points, while a male smoking increases his roommate's smoking probability by 5.7 percentage points. Likewise, Carrell et al. (2011) show that being randomly assigned a squadron in the Air Force Academy with highly fit peers increases healthy outcomes.
Few papers consider spillover effects from treatments. Basu and Meltzer (2005) explore how treatment choices may affect the utility of untreated family members, concluding that utility spillovers are important but the policy implications of the phenomenon raise equity concerns. Similar to our goal of characterizing intervention spillovers on outcomes, Angelucci and Di Maro (2010) describe how to design and evaluate field experiments to obtain valid estimates of treatment spillovers. As a demonstration, they evaluate spillovers from the Mexican conditional cash transfer program PROGRESA on food consumption in non-recipient households local to recipient households. They find significant increases in consumption among non-recipients that imply the subjects-only analysis of the program underestimated its effects by 12%.
We contribute to the literature in two ways. First, we provide estimates of significant treatment spillovers in clinical experiments regarding smoking and alcohol consumption. Such spillovers are of policy relevance in determining returns to treatments, but to our knowledge have not been previously estimated. We also utilize the trial's randomized allocation of treatments as an instrument for estimating causal behavioral spillovers between spouses, an element of the overall treatment spillover. Second, we employ our treatment spillover estimates in a cost effectiveness re-analysis of the interventions to show how accounting for spousal spillovers may affect cost effectiveness conclusions.
The rest of the paper proceeds as follows: in section I we formalize our model of spousal interaction, and in section II we describe the data and estimate treatment effects on the study subject populations. Sections III and IV estimate reduced form treatment effects on subjects' spouses and behavioral spillovers from subjects to spouses, respectively. Section V discusses the implications of our estimates for cost-effectiveness analysis and section VI concludes.
I. Model
Define the recipient of a randomized treatment as the "subject" and the recipient's spouse as the "spouse". A simultaneous equations environment where each spouse's behavior affects the other characterizes a couple's substance use. For couple , let the subject's substance use be determined as in the first equation below: by previous use, contemporaneous spousal use, and an effect due to treatment. Spousal substance use is symmetric except that since she is not assigned to treatment, her partner's treatment assignment is referenced.
Then ! is the direct treatment effect from the intervention while ! and ! are endogenous spousal peer effects. Direct treatment spillovers, represented by ! , are effects of the intervention on a subject's spouse that do not occur through changes in the subject's substance use outcome. For example, if a subject shares helpful information about quitting methods, this is a direct treatment spillover, but the extent to which those methods change spousal use through changes in the subject's use is not. Effects from lagged outcomes, parameters ! and ! , account for persistence in substance use. Since we have two endogenous variables (subject and spousal use) and only one instrument (treatment, due to random assignment), we cannot immediately estimate the full model to recover all structural parameters.
To characterize the total effect of the treatment on a subject's spouse we show the reduced-form equation for spousal use 3 . Now the estimating equation for spousal substance use is:
Then the term
gives the total effect of being the spouse of a subject who is randomized to treatment . Although it does not directly estimate any structural parameters, this is of interest as it captures previously unmeasured benefits of the treatment. If behavioral spillovers from the subject to the spouse do not exist ( ! = 0), the term reduces to the direct treatment spillover effect, ! . Finally, since treatment is randomly assigned in our interventions, we assume the composite error term is uncorrelated with ! so we can estimate the reduced form equation without further complications.
II. Data
We analyze data from two separate substance abuse studies, the Lung Health Study and the COMBINE Study. The studies have different strengths for our purposes. First, spillover effects may vary across behaviors and intervention types. The existing spillovers literature finds stronger spousal spillovers in smoking than in alcohol use (Meyler, Stimpson, and Peek, 2007) , so it is useful to examine effects in both contexts. Mechanically, LHS benefits from a large sample size and long follow-up period, while COMBINE's primary strength is its diversity of types of treatments, which permit investigation of how spillovers vary across pharmaceutical and behavioral interventions.
Lung Health Study
The Lung Health Study (LHS) was designed to test for effects of two interventions on lung function among adults age 35-60 at high risk of Chronic Obstructive Pulmonary Disease. The study's 5,887 participants were randomized into three groups: usual care (control), an "intensive state-of-the-art smoking cessation program" plus regular therapy with an inhaled bronchodilator (SIA), or the same smoking cessation therapy program but with a placebo bronchodilator (SIP) (Anthonisen, 1989) . Therapy interventions included personalized, physician-led evaluation, discussion of health implications, improved access to nicotine gum, and group sessions with family and friends. Both the SIA and SIP interventions incorporated a behavioral/therapy component, so all spouses of subjects not assigned to the control group may havebenefitted from secondary exposure to the treatments' behavioral components. The first stage of the study followed participants annually for five years, though later iterations extended that period.
We restrict our sample to the 3,873 subjects who reported being married at baseline, and give extra attention to the 1,391 married subjects with a smoker spouse at the study's onset. Some individuals reported a spousal smoking status despite not being married. Of these respondents, 5 were never married and 243 were widowed, separated, or divorced. 4 Group summary statistics for the full LHS sample as well as the married and married-to-smoker at baseline subsamples are presented in Appendix Table A1 . The average LHS respondent is 48.5 years old, has 1.6 years of postsecondary education, and is slightly overweight according to BMI. Only 37% of respondents are women, but twothirds are married and 36% of spouses smoke. Almost the entire subject sample smoked at baseline (those who did not were recently smokers) and subjects smoked nearly 30 cigarettes per day on average. Although t-tests find statistical differences between the full sample and the married or married-to-smoker subsamples, the differences are practically small; the main qualitative differences are that married subjects are less likely to be female, married-to-smoker subjects smoke more cigarettes per day, and both married subjects are slightly less educated than the full sample.
Balance on observables across treatments for the married sample and the marriedto-smoker sample is tested in Table A2 . The leftmost column gives the mean for the control subjects of each subsample while the next columns give the deviations for SIA and SIP treatments, respectively. Subject characteristics for these subsamples are balanced, as most differences between groups are small and statistically insignificant. The (non-placebo) bronchodilator group (SIA) has more women than the other treatments in the full spousal sample, and subjects in SIA married to baseline smokers smoked just under 2 more cigarettes per day than their usual care counterparts (one more per day than the SIP group). The bottom row of the table confirms that the counts of subjects within subgroups are similar across treatments.
COMBINE Study
The COMBINE Study was designed to test for interactions in the effectiveness of several alcoholism treatments. Participants were assigned to treatments where they received 16 weeks of any combination of a placebo, Naltrexone, or Acamprosate, and a combined behavioral intervention (CBI). Although the follow-up period continued for more than a year, information about the 1,375 subjects' peers was only collected 16 and 26 weeks after the intervention began (O'Hara et al, 1993) . Subject peer information includes the relationship description, drinking behavior, attitudes towards drinking and the intervention, as well as intensity of contact for up to 10 relations.
Unlike LHS, which primarily targeted improved lung health but acknowledged smoking cessation as a means to that end, COMBINE expressly sought reductions in problem drinking. Anton et al (2006) find that treatments including Naltrexone, Therapy/CBI, or both significantly reduced drinking as measured by their primary measures -percent days abstinent and time to first heavy drinking day -while Acamprosate did not improve drinking outcomes.
Descriptive statistics for the COMBINE sample in Table A3 below indicate some differences in observables between the full sample, married subjects, and subjects married to spouses who were reported as moderate or heavy drinkers at baseline (hereafter, "drinker spouses").
5 Married subjects, just over 45 percent of the full sample, were about 3 years older than the full sample average of 44.6 years old, had a half year more education than the mean 14.6 years, were more likely to be white and less likely to attend Alcoholics Anonymous (AA). Subjects married to drinker spouses were almost twice as likely to be female, were much less likely to attend AA, and drank fewer drinks per day but with a higher incidence of heavy drinking days. Subjects with a heavy drinking spouse at baseline accounted for about a tenth of the married subsample and almost 40% of the drinker spouse sample. Spousal drinking outcomes were collected as part of a survey in which a subject could indicate that his or her spouse was a recovering alcoholic, abstained, or was a light, moderate, or heavy drinker. Spouses listed as recovering alcoholics at baseline only comprised about one percent of spouses and were excluded from our analysis because of the response's uncertain implications for use. Baseline drinking intensity was balanced by treatment for both spouses and subjects. Each row of Table A4 provides the control mean as well as treatment differences and the F-statistic from an OLS regression on the dichotomous specified drinking outcome. Subject treatment assignment explains little of the variation in baseline spousal outcomes and even less in subject outcomes. The sole potential issue is that spouses of subjects in therapy treatments were 9 percentage points less likely to be light drinkers and 5 percentage points more likely to be heavy drinkers at baseline, so we control for baseline spousal drinking behavior. Ordered logit regressions of the categorical spousal drinking measures also yield no significant differences.
Effect of Treatments on Subjects
Before examining treatment spillovers, it is useful to contextualize the first order effects of the treatments on subjects. Table 1 presents treatment effects on smoking status among treatment subjects in LHS for different subgroups and specifications. From left toright the sample is restricted to unmarried subjects with no smokers in their households, married subjects, then subjects married to smoker spouses. For each group we present treatment effects conditioning only on wave dummies, demographics, a baseline smoking intensity measure (number of cigarettes per day), and random effects. Not shown are limited dependent variable models, which yield nearly identical marginal effects. Treatment effects range from a 19 to 28-percentage point reduction in smoking behavior due to the interventions. Effects were smallest for unmarried subjects without any smokers in the household, though effect sizes varied little between the full married sample and the subsample married to a smoker at baseline. The SIA and SIP interventions had similar effects, though the addition of the non-placebo bronchodilator had a significant return for the married-to-smoker at baseline group. Additional covariates have very little impact on effect sizes in all cases, reflecting the balanced covariates across treatment arms. The differential between the two leftmost columns and the others suggests that unless the intervention itself was more effective for married subjects (heterogeneity in ! ), the spouse-to-subject behavioral spillover and direct treatment spillover ( ! and ! ) are nonzero.
Treatment effects on subjects were smaller in the COMBINE study. Table 2 below gives the effect of the inclusion of each of the treatments, possibly as part of a multi-pronged approach. Effects listed are percentage point changes in the probability of heavy drinking pooled across 16 and 26 weeks after baseline. 6 For each subsample of subjects, effects are shown for the simple conditional mean adjusting only for an indicator at week 26 as well as a full set of covariates including baseline percent heavy drinking days, demographics, and a random effect. Consistent with prior work, treatments involving Naltrexone or Therapy induced the largest reductions in drinking across groups. Naltrexone was the most effective at reducing heavy drinking among unmarried subjects, but married subjects experienced larger reductions from therapy (though the effects are not statistically different). Randomization of subject for the COMBINE study appears to have been successful, as the addition of covariates has little effect on estimates.
III. Treatment Spillovers
The Lung Health Study reports spousal smoking status as a binary variable, so we consider linear and logit models of smoking status. The COMBINE data report categories of intensity of substance use, so we test for outcomes on the margin of heavy drinking and across all categories using ordered logit models. Since both studies have spousal outcomes for multiple post-treatment periods, our main specifications pool across waves but include period dummies and cluster standard errors at the individual level.
Effect of Having a Spouse Selected for Treatment: LHS
To test the reduced-form treatment effect on smoking for spouses of subjects assigned to the interventions, we estimate the equation below. The baseline Model 1 includes only treatment indicators, wave dummies ( ! ), and baseline smoking status (where not redundant given the sample). Model 2 adds subject age, sex, education, and BMI ( !(!) ! ) while Model 3 adds the random-effect term ( ! ) to control for unobserved heterogeneity. The tables report estimates of ! and ! , the spillover effects of treatment assignment on spousal smoking among spouses. Recall that these are not structural parameters, but rather the (reduced form) policy-relevant changes in spousal behavior due to the treatment. Table 3 presents the main OLS estimates of spousal spillovers for the specifications described above. Across all married couples, assignment to the SIA treatment (behavioral intervention + bronchodilator) decreased a spouse's smoking probability by 5.9 percentage points, and assignment to the SIP treatment (behavioral intervention + placebo) decreased a spouse's smoking probability by approximately 5 percentage points. Effects were larger among baseline smoker spouses, for whom we estimate a 12.5 percentage point decrease from SIA and a 12-percentage point decrease from SIP. These large effects are robust to specification choice as shown by the small changes across columns within each group. The similar magnitude of the two effects suggests that the pharmaceutical element of the bronchodilator does not add much (less than a percentage point) to the full spillover effect. This is perhaps not surprising if the primary intention of the medicine is to improve lung health rather than to change behavior and/or if subjects are unlikely to share experimental medication with their spouses. Figure 1 shows how the treatment effects evolve over time by plotting ! and ! as well as their 95% confidence intervals from separate regressions of Model 1 on the baseline smoker couples sample for each year post treatment. One year after treatment, SIA decreased smoking among spouses by 19.4 percentage points and SIP by 16 percentage points. Effects unsurprisingly shrink over time, but are still statistically significant for both treatments at approximately a 10-percentage point reduction in spousal smoking 5 years after treatment. Time-paths by treatment for the entire married sample are analogous, though the year 5 effect for SIP is no longer statistically significant.
Separate estimates by subgroups are presented in Table A5 . Treatment effects for the pooled treatments (SIA or SIP) are estimated using model 2 separately for wives (subject is male), husbands (subject is female), and spouses of subjects who are: younger ( ≤ 50), older ( > 50), high school educated or less, and more than high school educated. For each subgroup we also present results for the full married sample, baseline smoker spouses, and baseline non-smoker (N.S.) spouses. Overall there is little heterogeneity in effects except by education, where effect sizes are about 50% larger for spouses of subjects with greater than a high school degree, though the difference is not statistically significant. The lack of differential between husbands and wives is a slight departure from the results mentioned above in Eisenberg, Golberstein, and Whitlock (2014) , though their data were college students in same-sex roommate pairs rather than married couples. Patterns between columns vary little by baseline smoking status.
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Effect of Having a Spouse Selected for Treatment: COMBINE
The COMBINE study also induced treatment spillovers on spouses. Table 4 presents the effects of a subject's assignment to treatment including one of the listed interventions on his spouse's heavy drinking status. The effects are robust to specification choice but vary widely across samples. Among all spouses, only therapy had a statistically significant spillover effect of a 3.3 percentage point decrease in spousal heavy drinking. For the sample of moderate and heavy drinking spouses at baseline, therapy induced a much larger 13 to 14-percentage point decrease in heavy drinking rates. For this sample Naltrexone also has a practically significant impact estimate of 4 to 6 percentage points, though it is imprecisely estimated. These results contrast the subject impacts, where Naltrexone dominated in terms of behavioral effects. If spouse-to-spouse behavioral spillovers dominated the reduced form spillover effect, then we would expect Naltrexone to have the largest spillovers on spouses. Since therapy interventions have larger spousal effects and are likely more transferrable as direct spillovers between spouses, these results suggest that behavioral spillovers between spouses are likely not as important as direct treatment spillovers in higher alcohol-use couples. Since the spousal drinking measure provides more detail than just the dichotomous heavy drinking outcome, we examine how treatment affects drinking intensity across the spectrum of drinking intensity. Although ordered logit is a natural statistical choice here, for ease of interpretation we convert categories to continuous drinks per week and present OLS estimates in Table 5 . Our conversion is as follows: 0 drinks per week for abstainers, 3 for light drinking, 9 for moderate drinking, and 18 for heavy drinking. Therapy was the only intervention to have a statistical effect on spousal drinks per week, with an effect of 1 fewer drinks per week for the full spousal sample and just under 2 fewer drinks per week for the baseline drinker spouse sample. Ordered logit results (Table A7 ) follow the same pattern of statistical significance, with slightly more drop-off in significance and effect size when including random effects. The COMBINE study lacks the long post-treatment history of the LHS, but it is possible to examine spillovers separately in weeks 16 and 26. Results in Table A8 suggest that the therapy interventions did not have their full impact by the end of the 16-week therapy treatment. Week 26 reductions in heavy drinking were about twice the size of week 16 effects; 5 and almost 19 percentage point heavy drinking reductions for the full married and baseline drinker spouse populations, respectively. This stands in contrast to the weekly results for subjects (not shown), which changed little between weeks 16 and 26 and again saw larger effects for Naltrexone than therapy across the timeframe.
Finally, we test for heterogeneity in COMBINE treatment spillovers. Subgroup inferences are difficult due to the smaller sample size, but results by gender are presented in Table A9 . We again control for demographics and baseline use and estimate using the full sample and separately by baseline use status. Treatments are not combined as they were for LHS because the COMBINE study interventions were sufficiently distinct from each other. Reductions for Naltrexone and therapy are meaningfully larger for spouses of female subjects, who we assume to be husbands, though differences are not statistically significant. Baseline moderate or heavy drinker wives of subjects observe a reduction of 1.1 drink per week while husbands reduce consumption by almost 2.3 drinks per week. Focusing instead on a dummy for heavy drinking yields an identical pattern but with less statistical significance due to reduced identifying variation and small sample sizes.
IV. Behavioral Spillovers
We turn to instrumental variables to estimate the direct effect of subject drinking on spousal drinking. Since a subject and spouse's substance use are endogenously codetermined, OLS regression of spousal substance use on the subject's substance use will give a biased estimate of the causal behavioral spillover. To remedy this we use random treatment assignment as an instrument for subject behavior. The validity of the IV results depends on the exclusion restriction ! = 0 from the spouse's structural equation (2), that is, the treatment must only affect spouses via changes in the subjects' behavior. The plausibility of this assumption depends on the nature and delivery of the treatment in question. In the following sections we present behavioral spillover estimates for two assumptions regarding the validity of this assumption in LHS and COMBINE. 8 To estimate behavioral spillovers between spouses, we estimate the following two-stage relationship for each couple and using treatments ∈ as instruments:
The first stage outcome may be dichotomous (subject smoking or drinking status) or quasi-continuous (subject's average number of cigarettes smoked or drinks per unit of time). We focus on 2SLS estimates but IV probit marginal effects do not depart meaningfully from the presented results. Table 6 presents estimates of spousal behavioral spillovers using smoking status and cigarettes per day as endogenous measures of subject smoking and both SIA and SIP as instruments. Each parameter estimate (across rows and columns) is from a separate regression. The second set of rows of results estimates spillovers using the number of cigarettes smoked per day divided by the average number smoked per day (30) to showhow results change when using a continuous endogenous variable for improved suitability to the assumptions of 2SLS.
Case 1: Exclusion Restriction Holds
The biased OLS regression suggests that among baseline smoker couples, a subject's smoking makes his or her spouse in the full spousal sample 14.6 percentage points more likely to smoke and in the baseline smoker spouse sample over 30 percentage points more likely to smoke. In both samples, IV estimates of behavioral spillovers are about 50% larger than OLS estimates. Since the IV estimate is a local average treatment effect (LATE), our estimate suggests that the effects of spousal cessation on own cessation are particularly large when induced through these medical treatments. Alternatively, since the effect of the instrument on subjects and the potential direct spillover of the treatment/instrument onto spouses are likely both negative in this instance, the ratio of these should be positive and inflate IV estimates. Case 1 spillovers in COMBINE utilize all treatments (Acamprosate, Naltrexone, and therapy) as instruments and follow patterns similar to those in LHS (see Table 7 ). Biased OLS regressions are similar in magnitude to effects from the reduced form treatment spillovers (though smaller here) while 2SLS effects are large relative to other estimates, though not statistically significant. Heavy drinking by a subject increases the probability of spousal heavy drinking by 25.8 percentage points in the full spousal sample and 58.5 percentage points for spouses who were moderate or heavy drinkers at baseline. Although F-statistics are a reasonable 13.4 for the full spousal sample, we do not present results for the baseline drinker spouse sample because the F-statistics of 4.8 for this group are insufficient for valid inference. These estimates are again consistent with a large LATE and/or inflated estimates due to violation of the exclusion restriction. Using the same conversion of categories to numbers of drinks per month as described in the preceding treatment spillovers section and the same IV framework as above (but controlling for baseline number of drinks instead of a baseline heavy drinking indicator) we estimate that a heavy drinking subject increases spousal drinking by 10.93 (7.04) drinks per month for the married sample and 39.45 (30.66) drinks per month for the baseline moderate or heavy drinker spouse sample. These large effects indicate that the results in Table 7 are likely not simply due to the focus on outcomes around the cutoff for heavy drinking.
Case 2: Slight Violation of the Exclusion Restriction
To formally account for the possibility of the exclusion restriction not holding, we employ the methods described by Conley, Hansen, and Rossi (2012) and estimate the peer effect under various priors for the direct treatment spillover. Specifically, we assume the treatment directly decreases spousal smoking by at most ! (determining a lower bound on the treatment effect) and calculate the point estimate and 95% confidence interval for several levels of ! . We fix the upper bound of ! at 0 (no effect), so the upper range of confidence intervals remains fixed throughout the tables. We then report the union of these confidence intervals.
Each row in Table 8 gives the lower and upper bounds of the union of confidence intervals for the full spousal sample as well as baseline smoker samples for direct treatment effects bounded above by zero and below by ! . We contextualize the restrictions on ! by their percentage of a typical treatment effect on subjects, or 25 percentage points for LHS. Small ! floors (closer to zero) give confidence intervals that imply fairly large spillover effects, though not inconsistent with the estimates in case 1. If the treatment directly reduces smoking by at most half a percentage point, then confidence intervals range from a 12 to 27-percentage point behavioral spillover among all spouses and a 28 to 59-percentage point behavioral spillover for baseline smoker spouses. Confidence intervals begin to include zero for ! between -2.5 percentage points and -5 percentage points for all spouses and between -5 and -10 percentage points for baseline smoker spouses. Direct spillovers of up to 20 percentage points or more rule out little of the range of conceivable behavioral spillovers. Figures 2 and 3 (in the appendix) perform a similar exercise, though instead of finding bounds given a range of spillover parameters, we specify a normal prior for the direct spillover and arrive at a point estimate and confidence interval again using the methods described in Conley, Hansen, and Rossi (2012) . Following their example, we define the prior to be ( ! , ! ! ) and graph the results. The implications are similar to those presented in Table 8 , though confidence intervals are a bit more conservative than those in the table.
Plausible exogeneity for COMBINE requires that we allow direct spillovers to spouses of subjects who received the therapy treatment. This results in large confidence intervals for the behavioral spillover effect size due to the relatively small effect of therapy on subjects. We use the full sample 5-percentage point reduction from therapy on subject smoking as our benchmark, which is more conservative than the treatment's effect on the married subject sample. Allowing even a twentieth of a percentage point decrease directly from therapy treatments yields 95% confidence intervals that include 0 as well as implausibly large effects of +62 percentage points for the full spousal sample. Baseline drinker couple intervals (not shown, again due to sample size) are even more exaggerated but follow the same pattern. This section has taken two approaches to estimate novel causal effects of spousal health behavior spillovers. Assuming that the treatment spillovers on spouses only operate through the treated subjects suggests very large causal effects of health behaviors between spouses, even larger than suggested by naïve OLS specifications. We might have expected the IV estimates, which are meant to eliminate the impacts of selfselection of spouses and other spurious factors that would lead to large spousal correlations in smoking and drinking, to push the OLS estimates toward zero. However, a LATE interpretation of the finding that the IV results are larger than the OLS is that the effects of health behavior decisions on spouse's decisions are particularly large when induced by these medical treatments. We next examine the implications of our results for treatment evaluation.
V. Implications for Cost-Effectiveness
The implications of treatment spillovers for cost-effectiveness analyses are potentially large. Suppose, for example, that therapy-based treatments typically have greater spillovers than pharmaceutical interventions. In this case, even if a pharmaceutical intervention is more cost effective among subjects, the therapy treatment may be more socially cost effective. Spouses provide a useful starting point for social spillovers in cost effectiveness because marital pairs are well-defined and likely have sizeable individual effects, but more comprehensive assessments of networks may have more important spillovers overall as effects cascade across peer groups.
We calculate costs per additional cessation relative to usual care for LHS and COMBINE, also known as incremental cost-effectiveness ratios (ICERs). The incremental cost effectiveness with spillovers for treatment relative to with mean subject effectiveness , spillover population share m, and mean spillover effect size is given by
. Anthonisen et al. (2005) estimate that "a unit price of $2000 would probably cover the LHS smoking intervention including intensive initial counseling, nicotine replacement therapy, and the long-term maintenance program." We add an extra $500 for medication in the non-placebo bronchodilator intervention SIA and normalize LHS usual care to $0. The shorter-term COMBINE study's Medical Management and Placebo reference group cost $409, while the Acamprosate, Naltrexone, and Combined Behavioral Intervention/Therapy treatments incurred an additional $339, $262, and $143, respectively. Effect sizes are rounded from the tables in the preceding sections.
As seen in Table 10 , the SIP intervention (counseling and nicotine gum access, with placebo bronchodilator) was the most cost effective for subjects, with an estimated $9,524 per additional cessation, or 0.105 additional smoking quitters per $1,000 dollars of treatment. Subjects receiving the non-placebo bronchodilator observed around three quarters as many quits per thousand dollars, totaling $13,158 per quit. Including spousal smoking cessation for the 28% of the sample with a smoker spouse at baseline does not change the ordering of the treatments' cost effectiveness, but it reduces the cost per quit of SIA by $2,000 (a drop of 15.6%) and SIP by $1,300 (13.8%). Costs per quit reduce by similar percentages across treatment in this case because the SIP and SIA interventions had nearly identical effects on cessation for subjects and spouses. Anthonisen et al. (2005) . Costs of nicotine gum for some spouses not included.
The COMBINE study's variation in treatment effectiveness on subjects relative to spouses highlights the potential for misleading conclusions in cost effectiveness analysis. Ignoring cost, the most effective treatment for the full sample of subjects was Naltrexone, with a two-percentage point greater reduction in heavy drinking than CBI/Therapy. In contrast, CBI decreased heavy drinking among baseline drinker spouses by 8 percentage points more than Naltrexone. As such, for plausible ranges of costs for the two treatments and shares of subjects who were drinkers at baseline, the most cost effective treatment would flip from Naltrexone to CBI when switching from a subject-only to social cost effectiveness analysis. For example, for the observed 4% share of drinker spouses, if Naltrexone cost $590 (or $185 more than the reference group) this would be the case. In this experiment, however, the extra cost of Naltrexone was enough so that CBI was the most cost effective therapy with or without spousal consideration at $2,606 or $2,354 per quit, respectively. This implies a decrease in dollars per quit for CBI of $252, or 9.7 percent from the social perspective. The cases above emphasize three intuitive factors that determine the extent to which cost effectiveness ranking will change with a broadened social frame. First and foremost, treatments must have differently ranked effectiveness on subjects and on subjects' peers (ranking of the and varies). Second, the importance of differential spillovers increases with the proportion of spouses or other relations ( ) who share the condition or behavior treated by the intervention and, of course, the share of married subjects (or other peers). Finally, greater differentials in cost and cost-effectiveness ( ! − ! ) will naturally require more compensation in the factors above to induce a switch in effectiveness rankings.
VI. Conclusion
This paper leverages two RCTs that reduced unhealthy behaviors (tobacco use and alcohol use) to produce the first estimates in the literature of causal spillovers on (untreated) spouses in health behaviors. Our estimates suggest large spillover effects. Under standard instrumental variable assumptions, the effect of husband cessation on his wife is a 20 percentage point reduction in smoking and 25 percentage point reduction in the heavy drinking. The effects are consistent with the literature showing spillover effects of alternative social ties (e.g. college roommates in Eisenberg et al. 2014) and are at odds with some conclusions of research that was unable to leverage experimental data that argue spousal correlations in health behaviors are driven entirely by selection effects (assortative mating) (e.g. Clark and Etile 2006) .
We then discuss the implications of these spillovers for measuring the comprehensive benefits of health RCTs as well as comparative effectiveness among alternative treatment regimes. Our results suggest that the typical (implicit) assumption that health treatments and interventions only affect the treated and have no other benefit are incorrect, with the implication that typical measures of treatment benefits and effectiveness are too small for some treatments-in our example by upwards of 15%; however this effect is the "tip of the iceberg" because we are unable to assess spillovers on other social ties (friends, neighbors, co-workers, children, etc). These results have the implication that properly calculating comprehensive benefits of treatments and interventions could reverse prior decisions that some interventions would not be expected to pass traditional cost benefit (or effectiveness) thresholds for implementation. A second implication of our results for comparative effectiveness calculations is the possibility that some treatments are dominated by alternatives when estimating direct effectiveness (i.e. only on the treated) but dominate when estimating total social effectiveness (i.e. direct + indirect effects). These are important considerations for future efforts, accelerated by the ACA and PCORI, to more regular comparative effectiveness analysis between potential treatment regimes. 
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